Tabpharm Limited 07505793 false 2023-05-01 2024-04-30 2024-04-30 The principal activity of the company is that of dispensing, retail and online pharmacy Digita Accounts Production Advanced 6.30.9574.0 true 07505793 2023-05-01 2024-04-30 07505793 2024-04-30 07505793 core:RetainedEarningsAccumulatedLosses 2024-04-30 07505793 core:ShareCapital 2024-04-30 07505793 core:CurrentFinancialInstruments 2024-04-30 07505793 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 07505793 core:PatentsTrademarksLicencesConcessionsSimilar 2024-04-30 07505793 core:FurnitureFittingsToolsEquipment 2024-04-30 07505793 core:LandBuildings 2024-04-30 07505793 core:MotorVehicles 2024-04-30 07505793 bus:SmallEntities 2023-05-01 2024-04-30 07505793 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 07505793 bus:FilletedAccounts 2023-05-01 2024-04-30 07505793 bus:SmallCompaniesRegimeForAccounts 2023-05-01 2024-04-30 07505793 bus:RegisteredOffice 2023-05-01 2024-04-30 07505793 bus:CompanySecretary1 2023-05-01 2024-04-30 07505793 bus:Director1 2023-05-01 2024-04-30 07505793 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 07505793 core:PatentsTrademarksLicencesConcessionsSimilar 2023-05-01 2024-04-30 07505793 core:FurnitureFittings 2023-05-01 2024-04-30 07505793 core:FurnitureFittingsToolsEquipment 2023-05-01 2024-04-30 07505793 core:LandBuildings 2023-05-01 2024-04-30 07505793 core:MotorVehicles 2023-05-01 2024-04-30 07505793 core:OtherPropertyPlantEquipment 2023-05-01 2024-04-30 07505793 countries:EnglandWales 2023-05-01 2024-04-30 07505793 2023-04-30 07505793 core:PatentsTrademarksLicencesConcessionsSimilar 2023-04-30 07505793 core:FurnitureFittingsToolsEquipment 2023-04-30 07505793 core:LandBuildings 2023-04-30 07505793 core:MotorVehicles 2023-04-30 07505793 2022-05-01 2023-04-30 07505793 2023-04-30 07505793 core:RetainedEarningsAccumulatedLosses 2023-04-30 07505793 core:ShareCapital 2023-04-30 07505793 core:CurrentFinancialInstruments 2023-04-30 07505793 core:CurrentFinancialInstruments core:WithinOneYear 2023-04-30 07505793 core:PatentsTrademarksLicencesConcessionsSimilar 2023-04-30 07505793 core:FurnitureFittingsToolsEquipment 2023-04-30 07505793 core:LandBuildings 2023-04-30 07505793 core:MotorVehicles 2023-04-30 iso4217:GBP xbrli:pure

Registration number: 07505793

Tabpharm Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 April 2024

 

Tabpharm Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 7

 

Tabpharm Limited

Company Information

Director

Mr B Shah

Company secretary

Mrs M Shah

Registered office

39 Barnehurst Rd
Bexleyheath
Kent
DA7 6EY
 

Accountants

Affinity Associates (Flemmings) Limited
(Trading as Flemmings)
Chartered Accountants
76 Canterbury Road
Croydon
Surrey
CR0 3HA

 

Tabpharm Limited

(Registration number: 07505793)
Balance Sheet as at 30 April 2024

Note

2024
£

2023
£

           

Fixed assets

   

 

Intangible assets

4

 

1

 

1

Tangible assets

5

 

7,615

 

7,513

   

7,616

 

7,514

Current assets

   

 

Stocks

21,250

 

10,700

 

Debtors

6

65,272

 

63,741

 

Cash at bank and in hand

 

103,812

 

131,347

 

 

190,334

 

205,788

 

Creditors: Amounts falling due within one year

7

(198,087)

 

(200,288)

 

Net current (liabilities)/assets

   

(7,753)

 

5,500

Total assets less current liabilities

   

(137)

 

13,014

Provisions for liabilities

 

1,030

 

719

Net assets

   

893

 

13,733

Capital and reserves

   

 

Called up share capital

80

 

80

 

Profit and loss account

813

 

13,653

 

Total equity

   

893

 

13,733

For the financial year ending 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

 

Tabpharm Limited

(Registration number: 07505793)
Balance Sheet as at 30 April 2024

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 7 January 2025
 

.........................................

Mr B Shah

Director

 

Tabpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
39 Barnehurst Rd
Bexleyheath
Kent
DA7 6EY
United Kingdom

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in Sterling, which is the functional currency of the company.

Revenue recognition

Turnover shown in the profit and loss account represents amounts invoiced during the year, shown net of value added tax.

The company recognises revenue when:
i. The amount of revenue can be reliably measured;
ii. it is probable that future economic benefits will flow to the entity;
iii. and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Tabpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures, Fittings & Equipment

25% Straight line method

Leasehold Properties

Amortised over 5 years

Motor vehicles

25% Straight line method

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Website domain cost

Amortised over 10 years

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.

At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Defined contribution pension obligation

The company operates a defined contribution pension scheme. Contributions are recognised in the profit and loss account in the period in which they become payable in accordance with the rules of the scheme.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 8 (2023 - 7).

 

Tabpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

4

Intangible assets

Intangible assets
£

Total
£

Cost or valuation

At 1 May 2023

135

135

At 30 April 2024

135

135

Amortisation

At 1 May 2023

134

134

At 30 April 2024

134

134

Carrying amount

At 30 April 2024

1

1

At 30 April 2023

1

1

5

Tangible assets

Short leasehold land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 May 2023

2,329

87,221

11,978

101,528

Additions

3,862

1,731

-

5,593

Disposals

-

(7,589)

-

(7,589)

At 30 April 2024

6,191

81,363

11,978

99,532

Depreciation

At 1 May 2023

2,329

85,697

5,989

94,015

Charge for the year

772

1,582

2,994

5,348

Eliminated on disposal

-

(7,446)

-

(7,446)

At 30 April 2024

3,101

79,833

8,983

91,917

Carrying amount

At 30 April 2024

3,090

1,530

2,995

7,615

At 30 April 2023

-

1,524

5,989

7,513

 

Tabpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

6

Debtors

2024
£

2023
£

Trade debtors

42,175

41,805

Prepayments and accrued income

3,950

3,302

Other debtors

19,147

18,634

65,272

63,741

7

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Trade creditors

 

41,612

53,910

Corporation tax

 

6,093

5,422

Other taxes and social security

 

274

251

Director's current accounts

8

142,613

134,378

Other creditors

 

7,495

6,327

 

198,087

200,288

8

Related party transactions

Other transactions with the director

Mr B Shah
(Director and Shareholder)

An interest free loan has been provided by Mr B Shah. There is no formal repayment terms agreed for the loan.
However, Mr B shah will not demand repayment of the loan unless the company has funds to do so.

At the balance sheet date the amount due to Mr B Shah was £142,613 (2023 - £134,378)

No other transactions with related parties were undertaken such as required to be disclosed under Financial
Reporting Standard 102 Section 1A.